
    
      Randomized, double-blind, placebo-controlled, Phase 3 study of 52 weeks duration.

      Patients who fulfill the inclusion and exclusion criteria will be enrolled at up to 60 sites
      in the United States, Canada, Europe, South Africa, Asia, Australasia, and the Middle East.
      Patients will be randomized in a 2:1 ratio to LIB003 or placebo. The total study duration
      will be up to 63 weeks which includes up to a Screening Period and 52 weeks of study drug
      treatment. Following randomization patients will be dosed and seen in the clinic Q4W (â‰¤31
      days).
    
  